GALVmed harnesses the best available expertise and capabilities in academia, public research institutes and the commercial pharmaceutical sector to develop vaccines, medicines and diagnostics for the major livestock diseases impacting smallholders. In using an extensive network of partners to undertake the development work, GALVmed functions as a Product Development Partnership (PDP). A number of PDPs exist for human neglected tropical diseases, but GALVmed is the only veterinary PDP in existence. The end result of GALVmed’s product development work will be a comprehensive portfolio of smallholder animal health products. But for these to become widely available to smallholders a second complementary strand of work is undertaken – market development.
GALVmed’s market development activities are underwritten by the willingness of smallholders to pay the market price for effective livestock health products (particularly vaccines). Smallholder awareness, as well as vaccine distribution and vaccinator networks, first need to be developed on a small scale in pilots and field projects. Once these have demonstrated economic viability, larger market initiatives can be developed to bring in the private vaccine manufacturers to achieve and sustain the scale that can reach millions of smallholders.
To further enhance the sustainability and scalability of its work, GALVmed works to facilitate better smallholder animal health policies to promote widespread availability of effective and affordable products. The overall approach is therefore a comprehensive and integrated approach which enables an efficient market process to serve smallholders needs with these vital agricultural inputs.
Transformational improvement in the well-being and economic progression of smallholder livestock farmers.
We will contribute to the transformation of smallholder farmers’ lives by:
GALVmed subscribes to the highest professional and ethical values, which reflect sustainable impact on poor livestock keepers through: